|
| 37861407 | Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma. | Clin Cancer Res | 2024 |
| 36055895 | Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study. | Eur Urol | 2023 |
| 37751561 | Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. | J Clin Oncol | 2023 |
| 37220954 | Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report. | J Immunother Cancer | 2023 |
| 37290035 | Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. | J Clin Oncol | 2023 |
| 37150667 | Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy. | Clin Genitourin Cancer | 2023 |
| 37414620 | Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience. | Clin Genitourin Cancer | 2023 |
| 37344281 | Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study. | Clin Genitourin Cancer | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 36623239 | Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer. | JCO Precis Oncol | 2023 |
| 36779357 | Clinical, pathologic, and molecular features of amphicrine prostate cancer. | Prostate | 2023 |
| 36710146 | A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer. | Clin Genitourin Cancer | 2023 |
| 36528479 | Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]. | Eur Urol | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 36795962 | Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort. | J Urol | 2023 |
| 36564459 | Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2023 |
| 35998004 | Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma. | Cancer Immunol Immunother | 2023 |
| 34508246 | Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. | Nat Rev Urol | 2022 |
| 35397952 | Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. | Eur Urol | 2022 |
| 35778337 | Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. | Clin Genitourin Cancer | 2022 |
| 36601043 | Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis. | Eur Urol Open Sci | 2022 |
| 36169695 | Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer. | World J Urol | 2022 |
| 36028450 | Changes in skeletal muscle and adipose tissue during cytotoxic chemotherapy for testicular germ cell carcinoma and associations with adverse events. | Urol Oncol | 2022 |
| 36155169 | Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. | Clin Genitourin Cancer | 2022 |
| 36004667 | Enfortumab vedotin in the treatment of urothelial cancers and beyond. | Future Oncol | 2022 |
| 35131040 | Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. | Lancet Oncol | 2022 |
| 35015566 | Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. | J Clin Oncol | 2022 |
| 35181282 | Corrigendum to "Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium" [Eur Urol Focus 2021;7:1347-54]. | Eur Urol Focus | 2022 |
| 35029306 | Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy. | Br J Clin Pharmacol | 2022 |
| 35168844 | Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. | Eur Urol | 2022 |
| 35078711 | Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. | Clin Genitourin Cancer | 2022 |
| 34597472 | Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. | BJU Int | 2022 |
| 32771446 | Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium. | Eur Urol Focus | 2021 |
| 35387424 | A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy. | Adv Radiat Oncol | 2021 |
| 33683795 | Disparities in Cancer Care and the Asian American Population. | Oncologist | 2021 |
| 33849963 | Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. | Clin Cancer Res | 2021 |
| 33707179 | BiTE-ing into Prostate Cancer with Bispecific T-cell Engagers. | Clin Cancer Res | 2021 |
| 33755225 | Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. | Prostate | 2021 |
| 33923126 | Whole-Body [<sup>18</sup>F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687. | Tomography | 2021 |
| 33556233 | Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. | BJU Int | 2021 |
| 33551249 | Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. | Urol Oncol | 2021 |
| 34407973 | Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2021 |
| 34516663 | Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. | Prostate | 2021 |
| 34452927 | IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). | J Immunother Cancer | 2021 |
| 33991512 | Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EVâ¿¿201): a multicentre, single-arm, phase 2 trial. | Lancet Oncol | 2021 |
| 34370078 | Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. | World J Urol | 2021 |
| 34086042 | Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA. | JAMA Oncol | 2021 |
| 34051178 | Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. | Lancet Oncol | 2021 |
| 34355457 | Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. | Oncologist | 2021 |
| 33433743 | Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations. | Curr Treat Options Oncol | 2021 |